News for Altimmune, Inc. (0A4C.L)

ALT is approach a readout from IMPACT, a phase 2b study of pemvidutide in MASH.

ALT is set to conduct a virtual meeting over the course of May 27-28, organized by B. Riley. This event will facilitate discussions focusing on the company's st

We recently published an article titled 13 Best Multibagger Stocks to Invest in Now. Altimmune, Inc. (NASDAQ:ALT) was one of the stocks that was covered in that article. Wall Street analysts believe ALT has a 288% upside potential over the next 12 months. Altimmune, Inc.(NASDAQ:ALT) is a clinical-stage biopharmaceutical company. It focuses on developing treatments for […]

We recently published an article titled 13 Best Multibagger Stocks to Invest in Now. Altimmune, Inc. (NASDAQ:ALT) was one of the stocks that was covered in that article.

GAITHERSBURG, Md., May 19, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. ( ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based the

Altimmune (ALT) initiates Phase 2 trial for pemvidutide targeting Alcohol Use Disorder (AUD). The trial will involve approximately 100 subjects

Altimmune (ALT) has initiated the first phase of participant enrollment for its RECLAIM Phase 2 trial. This study is focused on assessing the effectiveness and

GAITHERSBURG, Md., May 14, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. ( ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based the

Altimmune (ALT) will participate in two major investor conferences in New York in 2025. The company will present at the H.C. Wainwright BioConnect Inves

Cash Position: Ended Q1 2025 with $150 million in cash, cash equivalents, and short-term investments, up from $132 million at year-end 2024.ATM Facility: Raise

Key Takeaways: Altimmune (ALT) is progressing towards vital milestones with its IMPACT Phase 2b NASH trial results. The company has secured a $100 millio

The following slide deck was published by Altimmune, Inc.

Altimmune Inc. (ALTI) announced a notable increase in its first-quarter revenue, reaching $58 million. This marks a rise from the $50.8 million recorded in the

Key Takeaways: Altimmune (ALT) is on track to release Q1 earnings with a projected EPS of -$0.34. Strong analyst sentiment with upward revisions and an O

**media[618865]**

GAITHERSBURG, Md., May 06, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. ( ALT), a late clinical-stage biopharmaceutical company, today announced that it will repo

Altimmune (ALT) to release Q1 2025 financial results on May 13, 2025. The company will host a conference call and webcast at 8:30 am ET on the same day.

GAITHERSBURG, Md., April 30, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. ( ALT), a late clinical-stage biopharmaceutical company, today announced that members of

Altimmune (ALT) management to participate in a fireside chat at the Citizens Life Sciences Conference on May 7, 2025. The session will be available via